# A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Study · id `cardio:ct-nct05739383` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05739383](<https://clinicaltrials.gov/study/NCT05739383>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05739383

Browse, organ or system: Heart; Brain; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Stroke; Diabetes and metabolic disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 14012 participants.

## Technical summary

Registry record NCT05739383. Randomized; quadruple masking; primary purpose prevention. Start 2023-03-09 (actual); primary completion 2029-04-16 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 14012 participants (enrolled count; ClinicalTrials.gov record NCT05739383, source copy `cardio:ctgov-nct05739383-2026-11-05`, retrieved 2026-11-18)
- Started: 2023-03-09 (actual) (ClinicalTrials.gov record NCT05739383, source copy `cardio:ctgov-nct05739383-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2029-04-16 (anticipated) (ClinicalTrials.gov record NCT05739383, source copy `cardio:ctgov-nct05739383-2026-11-05`, retrieved 2026-11-18)
- Completion: 2029-04-16 (anticipated) (ClinicalTrials.gov record NCT05739383, source copy `cardio:ctgov-nct05739383-2026-11-05`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; China; Colombia; Croatia; Czechia; Denmark; Estonia; France; Greece; Hong Kong SAR China; Hungary; India; Israel; Italy; Latvia; Lithuania; Malaysia; Mexico; Netherlands; Philippines; Poland; Portugal; Puerto Rico; Romania; Singapore; Slovakia; South Africa; Spain; Sweden; Switzerland; Taiwan; Thailand; Türkiye; United Kingdom; Vietnam (ClinicalTrials.gov record NCT05739383, source copy `cardio:ctgov-nct05739383-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05739383-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
- Condition: Primary Prevention of Atherosclerotic Cardiovascular Disease
- Intervention (Drug): Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Intervention (Drug): Placebo in 1.5ml
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: e046bd998abb2e4c988c5ea3119d068ed32fdeed33305554651fb1334c430604
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
